PALO ALTO, Calif.--(BUSINESS WIRE)--Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a clinical-stage biopharmaceutical company advancing novel therapies in immunology and oncology by targeting myeloid ...
A study suggests that lupus-like manifestations in patients with MDS/CMML frequently reflect clonal myeloid infiltration.
"We found that being treated at an academic center was associated with improved survival, suggesting that specialized care for CMML is an important aspect of treatment." — Douglas Tremblay, MD, Tisch ...
Earlier studies have shown the granulocyte-macrophage colony-stimulating factor (GM-CSF) neutralizing effect of lenzilumab may benefit CMML patients with RAS pathway mutations Study is intended to ...
FRANKFURT, Germany — A novel agent has shown promise in the treatment of chronic myelomonocytic leukemia (CMML), a rare, aggressive malignancy of myeloid cells with an inherent risk of transforming ...
Patients were treated in the dose-escalation portion of the Phase 1/2 study evaluating seclidemstat in combination with azacitidine Investigators reported a 43% overall response rate among 14 ...
Parallel Phase I Studies of Daunorubicin Given With Cytarabine and Etoposide With or Without the Multidrug Resistance Modulator PSC-833 in Previously Untreated Patients 60 Years of Age or Older With ...
BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), today announced the first patient was dosed with lenzilumab in the Precision Approach to Chronic Myelomonocytic ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback